Anteris Technologies Global news

The company is actively presenting at three prestigious healthcare investment conferences, indicating investor engagement and confidence in its lead product DurAVR® THV. Conference presentations by C-suite executives typically signal company momentum and are used to communicate progress and strategy to institutional investors.

The company achieved a significant regulatory milestone by securing French clearance for its pivotal clinical trial, enabling patient recruitment to commence. This represents progress in the company's clinical and regulatory strategy for its lead product DurAVR®, which is a positive development for advancing the device toward commercialization.

Company achieved significant milestones including $320 million capital raise, U.S. patient enrollment commencement in pivotal PARADIGM Trial, CMS reimbursement coverage securing, and continued European enrollment progress. These developments support advancement toward commercial launch and demonstrate strong execution on strategic objectives.

The company achieved a significant regulatory milestone by securing Medicare reimbursement eligibility for its pivotal clinical trial, which removes a major barrier to U.S. site activation and patient enrollment. This is expected to accelerate trial progress and commercialization prospects for its lead product DurAVR® THV.

Company achieved multiple significant milestones in 2025 including FDA IDE approval for PARADIGM Trial, successful clinical outcomes (100 patients at 30-day, 65 at 1-year), secured $320 million in capital including strategic investment from Medtronic, and advanced manufacturing capabilities with ISO 13485 certification. These developments demonstrate strong progress toward commercialization and clinical validation.